Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial
Hideka Inoue(Shiga University of Medical Science), Hiroshi Maegawa(Shiga University of Medical Science), Masahiro Yoshimura(Hyogo Prefectural Cancer Center), Keiko Kondo(Shiga University of Medical Science), Satoshi Ugi(Shiga University of Medical Science), Shogo Ida(Shiga University of Medical Science), Katsutaro Morino(Kagoshima University), Kiyoshi Murata(Surugadai University), Hisatomi Arima(University of Leicester), Osamu Sekine(Shiga University of Medical Science), Daisuke Sato(Shiga University of Medical Science), Natsuko Ohashi(Shiga University of Medical Science), Keiko Fuse(Shiga University of Medical Science), Katsuyuki Miura(Shiga University of Medical Science), Sachiko Tanaka‐Mizuno(Shiga University of Medical Science), Itsuko Miyazawa
Cited by 62
Related Papers
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
|JAMA|2014|982
Cardiovascular Disease and Risk Factors in Asia
|Circulation|2008|916
Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction
|Diabetes|2006|855
Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents
|Journal of Clinical Investigation|2005|805
A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen
|Journal of Human Hypertension|2002|722